Selection of a Surrogate Agent (Fluconazole or Voriconazole) for Initial Susceptibility Testing of Posaconazole against Candida spp.: Results from a Global Antifungal Surveillance Program

Ítems similars

• Use of Fluconazole as a Surrogate Marker To Predict Susceptibility and Resistance to Voriconazole among 13,338 Clinical Isolates of Candida spp. Tested by Clinical and Laboratory Standards Institute-Recommended Broth Microdilution Methods
  per: Pfaller, M. A., et al.
  Publicat: (2007)
• Cross-Resistance between Fluconazole and Ravuconazole and the Use of Fluconazole as a Surrogate Marker To Predict Susceptibility and Resistance to Ravuconazole among 12,796 Clinical Isolates of Candida spp.
  per: Pfaller, M. A., et al.
  Publicat: (2004)
• In Vitro Susceptibilities of Candida spp. to Caspofungin: Four Years of Global Surveillance
  per: Pfaller, M. A., et al.
  Publicat: (2006)
• Evaluation of the Etest and Disk Diffusion Methods for Determining Susceptibilities of 235 Bloodstream Isolates of Candida glabrata to Fluconazole and Voriconazole
  per: Pfaller, M. A., et al.
  Publicat: (2003)
• Evaluation of Etest and Disk Diffusion Methods Compared with Broth Microdilution Antifungal Susceptibility Testing of Clinical Isolates of Candida spp. against Posaconazole
  per: Diekema, Daniel J., et al.
  Publicat: (2007)